7 Botulinum Toxin Brands Compared by a Doctor

When Every Clinic Says "Botox"

You sit in a consultation room in Seoul and the physician mentions botulinum toxin for your forehead lines. You nod — you have had Botox before, back home. But the vial the nurse prepares looks different. The name on it is unfamiliar. You wonder, briefly, whether this is the same thing. Whether it will work the same way. Whether cheaper means worse.

This moment of uncertainty is remarkably common. It is also remarkably understandable. The word "Botox" has become so thoroughly genericized that patients use it to describe any neuromodulator injection, the way "Kleenex" stands in for tissue paper. But there are now at least seven distinct botulinum toxin products in clinical use worldwide, each with its own molecular profile, manufacturing process, and clinical behavior.

The uncertainty is not a sign of ignorance. It is a sign that the information environment has failed to keep up with the market.

---

The Reframe: Brand Is the Wrong Unit of Analysis

Most patients compare botulinum toxins by brand name. Botox versus Dysport. Xeomin versus Nabota. This framing feels intuitive — we compare brands in every other consumer context.

But neuromodulators are not consumer products. They are pharmaceutical tools whose clinical effect depends on an interaction between four variables: formulation (the molecule and its accessory proteins), dilution ratio (how concentrated the injected solution is), injection technique (depth, angle, volume per point, spacing), and individual anatomy (muscle mass, skin thickness, metabolism). Brand is a proxy for the first variable only. It tells you nothing about the other three.

This is the lens that clarifies most of the confusion: the outcome is a function of the system, not the ingredient.

---

The Molecules: What Actually Differs Between Products

Seven Brands, Four Molecules

All botulinum toxin products used in aesthetics contain botulinum toxin type A, which blocks acetylcholine release at the neuromuscular junction. But "type A" is a family, not a single entity. The seven major brands derive from slightly different strains and purification processes, yielding four recognized drug substances.

Drug Substance	Brand Names	Manufacturer
OnabotulinumtoxinA	Botox, Botox Cosmetic	Allergan (AbbVie)
AbobotulinumtoxinA	Dysport	Galderma (Ipsen)
IncobotulinumtoxinA	Xeomin, Bocouture	Merz Aesthetics
PrabotulinumtoxinA	Nabota (Jeuveau in the US)	Daewoong Pharmaceutical

Beyond these four, several Korean products use botulinum toxin type A with proprietary purification processes:

Product	Manufacturer	Notable Feature
Innotox	Medytox	Liquid formulation, no reconstitution
Coretox	Medytox	No animal-derived components, no human serum albumin
Hutox	Huons BioPharma	900 kDa complex, competitive pricing

Claim: These molecular differences are not merely taxonomic — they produce clinically observable differences in onset, diffusion, and duration.

Evidence: OnabotulinumtoxinA (Botox) is formulated as a 900 kDa complex that includes hemagglutinin and non-hemagglutinin accessory proteins. AbobotulinumtoxinA (Dysport) also retains accessory proteins but with a different complex size and potency-to-unit ratio. IncobotulinumtoxinA (Xeomin) is a pure 150 kDa neurotoxin with all accessory proteins removed. PrabotulinumtoxinA (Nabota) is a 900 kDa complex similar to onabotulinumtoxinA but manufactured through a distinct purification process. Published comparative studies — including the pivotal phase III trial for prabotulinumtoxinA — have demonstrated non-inferiority to onabotulinumtoxinA for glabellar lines, with similar onset profiles and duration.

Implication: The accessory protein content affects how the toxin diffuses through tissue after injection. Products with larger complexes may stay more localized; products without accessory proteins may distribute differently. This is why the same unit count of two different brands can produce different clinical fields of effect — and why unit conversion ratios are approximations, not equivalences.

---

Diffusion and Spread: Why It Matters Clinically

Claim: The diffusion characteristics of a neuromodulator determine not just efficacy but safety margins in different anatomical zones.

Evidence: AbobotulinumtoxinA (Dysport) is widely reported to have a broader diffusion field than onabotulinumtoxinA (Botox), which can be advantageous for large, flat muscle groups like the frontalis but requires more caution near the brow margin to avoid ptosis. IncobotulinumtoxinA (Xeomin), lacking accessory proteins, has a diffusion profile that some investigators describe as intermediate. The liquid formulation of Innotox eliminates reconstitution variability, which theoretically standardizes diffusion behavior. A 2019 split-face study comparing onabotulinumtoxinA and prabotulinumtoxinA in glabellar lines found comparable spread and efficacy at equivalent dosing.

Implication: A physician choosing between products for a specific area is not just picking a brand — they are selecting a diffusion profile that matches the anatomical target. Forehead lines covering a wide area may benefit from broader diffusion. Crow's feet near the lower eyelid require tighter control. This is why experienced injectors sometimes prefer different products for different facial zones in the same patient.

---

Onset and Duration: Setting Realistic Expectations

Claim: Onset timing and effect duration vary meaningfully between products, and individual patient metabolism adds another layer of variability.

Evidence: Dysport is commonly reported to have a faster onset (2–3 days) compared to Botox (3–5 days), though both reach peak effect at approximately 2 weeks. Xeomin's onset profile is similar to Botox. Duration across products generally ranges from 3 to 6 months, but individual variation is substantial. Some patients metabolize botulinum toxin faster, requiring re-treatment at 10–12 weeks rather than 16. A 2022 meta-analysis of neuromodulator duration found no statistically significant difference in longevity between onabotulinumtoxinA and prabotulinumtoxinA at the 16-week endpoint, though individual-level data showed meaningful variance.

Implication: Patients who feel their Botox "doesn't last as long as it used to" may benefit from switching to a different formulation — not because one brand is superior, but because the immune and metabolic response to a specific toxin complex can change over time. This is also why some physicians rotate between brands, particularly for patients who develop relative resistance.

---

Korean-Manufactured Neuromodulators: The Evidence

Korea is not just a consumer of botulinum toxin — it is a major manufacturer. This deserves a separate examination because international patients arriving in Seoul often encounter Korean brands for the first time and need a framework for evaluation.

Nabota (Daewoong Pharmaceutical) received US FDA approval in 2019 under the brand name Jeuveau, marketed specifically for aesthetic use. Its phase III trial enrolled over 500 subjects and demonstrated non-inferiority to onabotulinumtoxinA. It holds KFDA, FDA, and CE certifications. In Korea, Nabota is one of the most widely used neuromodulators in aesthetic clinics.

Innotox (Medytox) is the world's first liquid botulinum toxin formulation. By eliminating reconstitution, it removes a significant source of inter-clinic variability — different physicians reconstitute powder toxins with different saline volumes, affecting concentration and diffusion. Innotox uses a proprietary polylysine stabilizer instead of human serum albumin, which some practitioners view as advantageous for patients concerned about albumin-derived proteins.

Coretox (Medytox) is formulated without animal-derived components and without human serum albumin, using a plant-derived stabilizer. It has gained traction in markets where patients or regulators prefer products free of animal-origin excipients.

Hutox (Huons BioPharma) is a 900 kDa botulinum toxin complex with competitive pricing and growing international distribution. It holds KFDA certification and is expanding its clinical evidence base.

The cost advantage of Korean neuromodulators is real — typically 30–50% lower than Allergan Botox — and reflects manufacturing scale and domestic competition, not compromised quality. Korean pharmaceutical companies operate under KFDA standards that are recognized as equivalent to FDA and EMA standards by international regulatory bodies.

---

Why the Same Brand Produces Different Results in Different Hands

This is perhaps the most important point in this entire article, and the one most patients underestimate.

Claim: Injection technique and dilution ratio contribute more to outcome variability than brand selection.

Evidence: A 2020 survey of board-certified dermatologists and plastic surgeons across 12 countries found that dilution ratios for onabotulinumtoxinA varied from 1 mL to 4 mL of saline per 100-unit vial. At 1 mL dilution, each 0.1 mL injection delivers 10 units in a concentrated bolus. At 4 mL dilution, the same 0.1 mL delivers only 2.5 units in a more diffuse solution. The clinical effect — localization versus spread, intensity versus subtlety — differs substantially. Separately, injection depth (intradermal versus intramuscular), angle of entry, number of injection points, and spacing between points all modify the outcome. Two physicians using the identical brand, identical total units, and identical dilution can produce meaningfully different results based on technique alone.

Implication: This is why chasing the "best brand" is the wrong optimization target. A skilled injector using any well-manufactured, certified botulinum toxin will produce better results than an unskilled injector using the most expensive product on the market. The brand is a controlled variable. The technique is the active variable.

---

What International Patients Should Ask

If you are traveling to Korea for neuromodulator treatment — or receiving it anywhere — the following questions reveal more than the brand name:

1. Which specific product are you using, and what is the active molecule? This tells you whether you are receiving onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, or prabotulinumtoxinA.

2. What is your dilution ratio? This tells you how concentrated the injection will be and helps you understand expected diffusion.

3. How many units are you planning for each area? This is the most important dosing question. Forehead, glabella, crow's feet, and masseter all require different unit ranges.

4. How do you adjust for my specific anatomy? A physician who examines your muscle mass, skin thickness, and existing asymmetry before determining dosing is working individually, not from a template.

5. What is the expected onset and duration for this product? This sets realistic expectations and helps you plan follow-up.

---

Where the Evidence Ends

Here is what we do not yet know with certainty.

There are no large, multi-arm randomized controlled trials directly comparing all seven brands head to head in the same patient population. Most comparative data comes from two-arm studies — typically a newer product versus onabotulinumtoxinA as the reference. Non-inferiority has been demonstrated for several products, but non-inferiority is not the same as equivalence, and it does not capture the subtler clinical differences that experienced injectors report.

Much of the practical differentiation between brands — which spreads more, which feels "smoother," which lasts longer in masseters versus glabella — is based on clinical experience, expert consensus, and pattern recognition rather than controlled trial data. This does not make it unreliable. It means the evidence is experience-dense but trial-sparse.

The question of long-term immunogenicity — whether repeated use of one formulation increases the risk of developing neutralizing antibodies compared to another — remains incompletely answered. There is theoretical reason to believe that products with fewer accessory proteins (like Xeomin) might carry lower immunogenic risk, but the clinical significance of this in aesthetic dosing remains debated.

---

The Question That Matters

The next time someone asks you which botulinum toxin brand is the best, consider redirecting the question: What are you trying to achieve, in which area, and who is doing the injecting?

The answer to that question will determine your outcome far more than the name on the vial.

---

This article is written by a practicing physician for informational purposes. It is not a substitute for medical consultation. Product availability, brand names, and regulatory status vary by country.

Related reading: Dermal Filler Brands: A Physician's Guide — a companion guide to filler selection by physical properties. Why Korea for Medical Care — why Seoul leads in aesthetic medicine.